|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3600 AUD | 0.00% |
|
-6.49% | -44.62% |
| 21/07 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| 20/07 | Recce Pharmaceuticals Extends Share Purchase Plan Closing Date | MT |
| Market Cap | 11Cr 7.54Cr 6.62Cr 6.16Cr 5.65Cr 11Cr 726.02Cr 73Cr 29Cr 356.94Cr 28Cr 28Cr 1.23TCr | P/E 2026 * |
-6x | P/E 2027 * | -2.25x |
|---|---|---|---|---|---|
| Enterprise Value | 12Cr 8.1Cr 7.12Cr 6.62Cr 6.07Cr 11Cr 780.37Cr 79Cr 31Cr 383.66Cr 30Cr 30Cr 1.33TCr | EV / Sales 2026 * |
12.1x | EV / Sales 2027 * | 19.8x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | -6.49% | ||
| Current month | -11.11% | ||
| 1 month | -21.74% | ||
| 3 months | -29.41% | ||
| 6 months | -45.45% | ||
| Current year | -44.62% |
| 1 week | 0.35 |  | 0.38 |
| 1 month | 0.35 | | 0.44 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/02/26 | Expiration | Chief Executive Officer | 22,50,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 7,45,962 | 0.3217% | ||
| 21/11/24 | Buy | Chief Technology Officer | 16,00,000 | 0.6900% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -6.49% | -0.69% | -47.06% | 7.52Cr | |
| +1.25% | +1.82% | +49.06% | +161.38% | 1,05700Cr | |
| +1.29% | +3.92% | +55.08% | +53.70% | 62TCr | |
| +0.66% | +1.77% | +35.72% | +80.89% | 45TCr | |
| +1.60% | +6.25% | +33.95% | +29.84% | 34TCr | |
| -0.60% | +1.52% | +35.68% | +39.76% | 30TCr | |
| -0.14% | +0.60% | +16.17% | +17.53% | 26TCr | |
| +0.09% | -2.82% | -28.29% | -41.71% | 22TCr | |
| +1.37% | +2.88% | +22.24% | +60.22% | 20TCr | |
| -0.64% | -3.13% | +14.91% | +67.50% | 16TCr | |
| Average | +0.55% | +0.05% | +23.38% | +42.20% | 36.14TCr | |
| Weighted average by Cap. | +0.86% | +1.57% | +35.88% | +77.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 95.58L 66.84L 58.7L 54.59L 50.1L 94.13L 64Cr 6.48Cr 2.53Cr 32Cr 2.51Cr 2.46Cr 109.41Cr | 81.91L 57.28L 50.31L 46.79L 42.93L 80.67L 55Cr 5.56Cr 2.17Cr 27Cr 2.15Cr 2.1Cr 94Cr |
| Net income | -1.87Cr -1.31Cr -1.15Cr -1.07Cr -97.94L -1.84Cr -125.83Cr -13Cr -4.95Cr -62Cr -4.91Cr -4.8Cr -213.89Cr | -4.72Cr -3.3Cr -2.9Cr -2.7Cr -2.47Cr -4.65Cr -317.84Cr -32Cr -13Cr -156.26Cr -12Cr -12Cr -540.28Cr |
| Net Debt | 80.7L 56.43L 49.57L 46.09L 42.3L 79.47L 54Cr 5.47Cr 2.14Cr 27Cr 2.12Cr 2.07Cr 92Cr | 5.46Cr 3.82Cr 3.36Cr 3.12Cr 2.86Cr 5.38Cr 367.88Cr 37Cr 14Cr 180.86Cr 14Cr 14Cr 625.33Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | A$0.3600 | 0.00% | 65,425 |
| 23/26/23 | A$0.3600 | +2.86% | 2,13,680 |
| 22/26/22 | A$0.3500 | -5.41% | 1,86,448 |
| 21/26/21 | A$0.3700 | +2.78% | 1,44,692 |
| 20/26/20 | A$0.3600 | -5.26% | 4,16,858 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
